Skip to content
value.today

Regulus Therapeutics Inc.

RGLSUnlisted company
$26 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

Regulus Therapeutics Inc. timeline

1 events, 2012
  1. 2012
  2. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of Regulus Therapeutics Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Regulus Therapeutics Inc.

Acquisitions and changes
No longer listed: ticker RGLS is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$23 M$46 M$70 M$93 M20202021202220232024

World rank over time

▼ down 2,983 places since 2020
2020-01-01: #24824#24,82420202021-01-01: #18743#18,74320212022-01-07: #27445#27,44520222022-12-25: #29183#29,18320222023-07-30: #28211#28,21120232024-01-05: #27807#27,8072024

Rank in USA: #4,462 (Jan 2020) · #3,775 (Jan 2021) · #4,982 (Jan 2022) · #5,261 (Dec 2022) · #5,064 (Jul 2023) · #4,297 (Jan 2024)

Mutual funds holding Regulus Therapeutics Inc.#

1 funds hold shares worth $0 M. Since their previous reports 0 added shares and 0 sold.
Mutual funds holding Regulus Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 The Gabelli ABC FundGabelli Funds, LLC60,000$0 M—0.01%no changeJun 30, 2026

As of Jun 30, 2026

Markets and events: Regulus Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-06-13
1.8 M
1.35 days to cover
Shares sold short, last 15 reportsAll stocks →

Trading halts

  • 2025-06-24 23:50 UTC, code D, resumed 04:00 UTC
  • 2025-04-30 10:55 UTC, code T3, resumed 11:30 UTC

Fails to deliver

  • : 570 shares at $8.20
  • : 17,945 shares at $8.22
  • : 413 shares at $7.94
  • : 4,464 shares at $7.93
  • : 9,949 shares at $7.91

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Regulus Therapeutics Inc.🇺🇸$26 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Profile updated:
Nov 14, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Regulus Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Regulus Therapeutics Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Regulus Therapeutics Inc.? Suggest a correction